NYSE: $BMY A Major Milestone in Cancer Research Bristol Myers Squibb (BMS) has officially announced positive topline results from an interim analysis of the Phase 3 ACTION-1 clinical trial. This study evaluated the safety and efficacy of RYZ101 (lutetium Lu 177 dotatate) in patients suffering from gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Understanding the ACTION-1 Trial The…